Heart Failure

Richard A. Chazal, MD, who was the ACC president at the time of the of the most recent ACC conference, revealed which presented studies he believes could change medical practice in the near future. He also discussed how low LDL cholesterol level guidelines will go.

Robert Roswell, MD, of NYU School of Medicine, discussed how much a physician's gut really comes into play when diagnosing chest pain at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

Using the database from the 40-country, double-blind phase 3 ARISTOTLE study, which has been around for over 5 years, a sub-analysis was conducted by Renato Lopes, MD, PhD, professor of Medicine at Duke University in Durham, North Carolina and colleagues.

Steven Zelenkofske, DO, vice president of US Medical Affairs at AstraZeneca, talked with MD Magazine about the CVD-REAL study where researchers examined patients with type 2 diabetes taking the new class of diabetes drug, SGLT-2 inhibitors. Positive outcomes were reported with dapagliflozin, canagliflozin, and empagliflozin.

The Absorb GT1 Bioresorbable Vascular Stent raised concerns at the FDA.

Drugs were as effective in CTO patients as PCI, Korean study found.

Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, detailed study results for sacubitril/valsartan the first angiotensin receptor neprilysin inhibitor to be approved by the FDA for its indication.

Fainting is common, but how should physicians treat it?

A Mass General team reports high accuracy with non-invasive CAD test.

Endotracheal intubation may do more harm than good.

Could cyber-terorrists turn a cardiac pacemaker into a weapon? It sounded like fiction until the FDA and a device maker today announced that they had fixed a popular device precisely to prevent that from happening.

A retrospective analysis of nutrition studies showed magnesium can reduce heart failure and diabetes risk. The key is dosage, a team found.

By the time patients need a left ventricular assist device their condition has already worsened considerably. With the help of a combination of technology and medication there is some research to show that improvement is possible in many patients.

Pending further research a new powerful pharmaceutical combination could make a significant difference in the treatment of patients with a left ventricular assist device.